Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Microsatellite Stable (MSS) Colorectal Cancer
Phase of Trial: Phase I
Latest Information Update: 04 Apr 2018
At a glance
- Drugs Spartalizumab (Primary) ; Regorafenib
- Indications Adenocarcinoma; Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 19 Feb 2018 Planned End Date changed from 11 Nov 2019 to 31 Aug 2018.
- 19 Feb 2018 Planned primary completion date changed from 11 Nov 2019 to 31 Aug 2018.
- 20 Jun 2017 Status changed from not yet recruiting to recruiting.